


Retriever Medical Receives Australian Patent for ClotHound ACE™ Thrombectomy Systems, boosting IP portfolio globally

Retriever Medical fortifies global IP presence with Australian Patent for ClotHound ACE Thrombectomy Systems, reinforcing leadership in mechanical thrombectomy.

LAS VEGAS, NEVADA, UNITED STATES, March 12, 2024 /EINPresswire.com/ -- Retriever Medical, (www.rtvmed.com) a pioneer in mechanical thrombectomy systems, proudly announces the recent allowance of [Australia Patent Application No. 2018352118](#) by the AU

[Patent Office](#). This significant milestone underscores Retriever Medical's commitment to innovation and further solidifies its position as a leader in the field of mechanical thrombectomy.



Introducing the ClotHound ACE Gold for PE and ClotHound ACE Blue for DVT: Innovations in thrombectomy technology from Retriever Medical.

“

This allowance of the Australia patent marks another significant achievement for Retriever Medical, reinforcing our commitment to advancing medical innovation.”

Ben Bobo

The forthcoming issuance of the Australia patent further enriches Retriever Medical's growing patent portfolio, which now comprises eight (8) issued U.S. and foreign patents, in addition to ten (10) pending U.S. patent applications and ten (10) pending foreign patent applications across various jurisdictions, including the European Community, Hong Kong, Canada, Japan, China, and Mexico.

Australia Patent Application No. 2018352118, which closely aligns with the previously issued thrombectomy systems

developed by Retriever Medical. Specifically, the patent encompasses the groundbreaking [Retriever Medical ClotHound ACE thrombectomy systems](#), including the ClotHound ACE Gold and ClotHound ACE Blue Systems. These systems are meticulously designed to provide Active Controlled Expansion (ACE) through two independently moveable uni-axial spheres, facilitating

the disruption, mobilization, capture, and removal of thrombus from the lungs and legs, regardless of its consistency.

[The Retriever Medical ClotHound ACE thrombectomy systems](#) offer a multitude of advantages over conventional alternatives. With features such as a dual sphere design with distal embolic protection, physician-controlled ACE functionality, single device placement for continuous thrombus removal, and integrated mechanical spheres alongside a large bore aspiration catheter, these systems ensure enhanced procedural efficiency, reduced blood loss, and improved patient outcomes.

"This allowance of the Australia patent marks another significant achievement for Retriever Medical, reinforcing our commitment to advancing medical innovation," stated Ben Bobo, CEO of Retriever Medical. "The broad scope and implications of our intellectual property underscore the transformative impact of our ClotHound technology platform in addressing critical clinical needs."

About Retriever Medical:

Retriever Medical, Inc. was founded with a vision to revolutionize the field of interventional medicine through the development of innovative surgical systems, including the ClotHound thrombectomy systems. Committed to improving patient outcomes and procedural efficiency, Retriever Medical continues to drive innovation and excellence in healthcare.

Retriever Medical's trademarks include Retriever Medical the Retriever Medical logo, ClotHound, ClotHound Blue, ClotHound Gold, ClotHound ACE, ACE, and Blood Genie. DogCurve, DogLeg, and DogTail are registered trademarks.

For more information, please visit www.rtvmed.com.

Investors Contact:

Ben Bobo

Phone: 714.654.2367

Email: bbobo@rtvmed.com

Safe Harbor Statement

This press release includes statements that look forward in time or that express management's beliefs, expectations, or hopes. Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include but are not limited to, the anticipated approval of pending and future patent applications related to Retriever Medical's ClotHound ACETM, BloodHoundTM, and Blood GenieTM Technology, the Company's future patent application filings and the protection of the Company's intellectual

property provided by any patents that issue. These statements are based on current information and beliefs and are not guarantees of future performance. Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include that pending and future patent applications related to Retriever Medical's ClotHound™, BloodHound™, and Blood Genie™ Technology may not result in an issued patent, that the issuance of any patents may be delayed, that the allowed claims, if any, may not be in line with the Company's expectations, that the Company may not be successful in enforcing its patents, and the risk factors detailed from time to time in the Company's periodic Securities and Exchange Commission filings. By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company's disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.

Ben Bobo
Retriever Medical, Inc.
+1 714-654-2367
bbobo@rtvmed.com

This press release can be viewed online at: <https://www.einpresswire.com/article/695078494>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.